A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon Compared to GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1DM)

Trial Profile

A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon Compared to GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1DM)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon
  • Indications Hypoglycaemia
  • Focus Adverse reactions; Registrational
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 07 Dec 2017 According to a Zealand Pharma media release, results are expected in Q2 2018, ahead of previous expectations.
    • 08 Nov 2017 According to a Zealand Pharma media release, status changed from recruiting to active, no longer recruiting.
    • 10 Jul 2017 Planned End Date changed from 19 Dec 2017 to 27 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top